Clinical trials: Schizophrenia and Disorders With Psychotic Features
Schizophrenia
Once Weekly D-cycloserine for Schizophrenia
This is a parallel-group, placebo-controlled trial examining the cognitive effects at weeks 1, 4, \& 8 of once-weekly oral D-cycloserine 50 mg added to a stable dose of antipsychotic for 8 weeks in adult outpatients with…
- Trial name
- NCT00964041
- Testing
- D-cycloserine
- Where
- United States
- Sponsor
- Massachusetts General Hospital
Psychosis
Niapsan as Add -on Therapy to Antipsychotic Treatment in First Episode Psychosis
The purpose of this study is to help understand if by adding Niaspan FCT (study drug) to antipsychotic medications will it help maintain or improve cognitve functioning.
- Trial name
- NCT01720095
- Testing
- Niaspan
- Where
- Canada
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Nova Scotia Health Authority
Mental Illness, Schizophrenia
Measuring Beliefs and Norms About Persons With Mental Illness
Survey experiment to estimate drivers of mental illness stigma
- Conditions
- Mental Illness, Schizophrenia, Bipolar Disorder, Depression
- Trial name
- NCT03656770
- Testing
- Survey questionnaire
- Where
- Uganda
- Volunteers
- 1,782 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Schizophrenia, Competence
Competence Ability Study in People With Schizophrenia
The goal of this research is to understand whether schizophrenic patients are capable of comprehending clinical trial consent form or influenced by disease, also after intensified educational illustration for "understanding of…
- Trial name
- CompSchizo (NCT01045629)
- Testing
- Consent form education
- Where
- Taiwan
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Taichung Veterans General Hospital
Schizophrenia, Schizophreniform Disorder
Omega-3 Dietary Supplements in Schizophrenia
This 16-week placebo-control study looks to investigate whether patients with schizophrenia for two years or less may benefit from omega-3 supplements.
- Conditions
- Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- NCT01786239
- Testing
- Risperidone, Omega-3 capsules
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Delbert Robinson
Schizophrenia / Schizoaffective Disorder
NST-SPARK Open-Label Phase 1 STTR (IGNITE)
Schizophrenia Spectrum disorders (SSD) are among the most devastating psychiatric disorders. Prominent negative symptoms such as low motivation, anhedonia, asociality, and emotional flattening are experienced by up to 60% of…
- Trial name
- IGNITE (NCT07593456)
- Testing
- NST-SPARK
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- North Shore Therapeutics, Inc.
Schizophrenia / Schizoaffective Disorder, Schizophrenia and Disorders With Psychotic Feature
Building a Computational Model of Auditory Hallucinations
Some people hear voices or sounds that other people cannot hear; these are called auditory hallucinations. The study aims to understand what is happening in the brain when this occurs and will use brain scans to learn more.
- Conditions
- Schizophrenia / Schizoaffective Disorder, Schizophrenia and Disorders With Psychotic Feature, Psychosis, SCHIZOPHRENIA 1 (Disorder)
- Trial name
- CLARITY WP1 (NCT07820553)
- Volunteers
- 146 people, healthy volunteers welcome
- Sponsor
- King's College London
Schizophrenia
[18 Fluorine(F)]DOPA Determinants and Predictors of Treatment Response in Psychosis
The first purpose of this study is to determine if dopamine synthesis capacity is significantly lower in treatment non-responders from illness onset relative to treatment responders.
- Trial name
- DPTP (NCT02880995)
- Testing
- PET scan, clinical scale, 6 weeks of treatment with amisulpride
- Where
- 2 sites in South Korea
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Diabetes Mellitus, Bipolar Disorder
Improving Outcomes for Individuals With Serious Mental Illness and Diabetes
This project tests a model for improving illness self-management among persons who have both serious mental illness and diabetes and will be performed within a primary care setting at a safety net hospital system.
- Conditions
- Diabetes Mellitus, Bipolar Disorder, Depression, Psychotic Disorders
- Trial name
- TTIM (NCT01410357)
- Testing
- Targeted Training in Illness Management (TTIM)
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Case Western Reserve University
Psychosis
Efficiency of a Composite Personalised Care on Functional Outcome in Early Psychosis
Chronic psychosis, including schizophrenia is now viewed as a progressive disorder where cognitive deficits predate the clinical onset.
- Trial name
- PSYCARE (NCT05796401)
- Testing
- Cognitive training, Personalized neuroprotective strategies : Vitamin B12, folinic acid, Omega 3, NAC, Treatment as usual (TAU)
- Where
- 13 sites in France
- Volunteers
- 500 people
- Sponsor
- Centre Hospitalier St Anne
Schizophrenia, Schizo Affective Disorder
The Efficacy of Neural Stimulation in Individuals With Schizophrenia
The purpose of this study is to understand the relationship between psychotic symptoms and social functioning in individuals with schizophrenia spectrum disorders.
- Trial name
- NCT05746494
- Testing
- tDCS
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- The University of Texas at Dallas
Bipolar Disorder, Schizophrenia
Implementation of Illness Management and Recovery in Mental Health Services
The purpose of this study is to examine the barriers and facilitators of implementing Illness Management and Recovery (IMR) in Norwegian mental health services.
- Conditions
- Bipolar Disorder, Schizophrenia, Affective Disorders, Psychotic, Mood Disorders
- Trial name
- NCT02077829
- Testing
- Illness Management and Recovery
- Where
- Norway
- Volunteers
- 40 people
- Sponsor
- University Hospital, Akershus
Schizophrenia, Schizoaffective Disorder
A Study of the Cataractogenic Potential of Seroquel and Risperdal in the Treatment of Participants With Schizophrenia or Schizoaffective Disorder
This Phase IV, randomized, parallel-group study is designed to evaluate the cataractogenic potential of quetiapine fumarate (SEROQUEL) compared with that of a putative non-cataractogenic antipsychotic medication risperidone…
- Trial name
- NCT00206102
- Testing
- quetiapine fumarate, risperidone
- Where
- 63 sites in United States
- Volunteers
- 1,098 people
- Sponsor
- AstraZeneca
Serious Mental Illness, Psychotic Disorder
Changing Lives and Changing Outcomes-9 at Worcester Recovery Center and Hospital
People with serious mental illness (depression, bipolar, and schizophrenia spectrum disorders) have high rates of repeated criminal legal involvement and psychiatric hospitalizations.
- Conditions
- Serious Mental Illness, Psychotic Disorder, Depression, Bipolar
- Trial name
- CLCO-9 (NCT07359157)
- Testing
- Changing Lives and Changing Outcomes-9
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Massachusetts General Hospital
Affective Disorders, Anxiety Disorders
Routine Outcome Monitoring in Mental Health Outpatient
Scientific Background: Inherent gaps exist between the worlds of research and clinical therapy, especially in mental-health systems.
- Conditions
- Affective Disorders, Anxiety Disorders, Psychotic Disorders, Personality Disorders
- Trial name
- ROM-Shalvata (NCT02095457)
- Testing
- Frequent monitoring and feedback
- Where
- Israel
- Volunteers
- 900 people
- Sponsor
- Shalvata Mental Health Center
Schizophrenia
Glucose Regulation During Risperidone and Olanzapine Treatment
The overall purpose of this research is to look at how two of the most commonly prescribed newer antipsychotic medications, risperidone and olanzapine, affect substances in the body such as glucose and insulin.
- Trial name
- NCT00006195
- Testing
- risperidone, olanzapine
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Center for Research Resources (NCRR)
Schizophrenia, Schizoaffective
An Open Trial of Cysteamine Treatment in Schizophrenia
The purpose of this study is to determine the tolerability of the medication cysteamine bitartrate on schizophrenia patients and to evaluate the effect of the medication on the symptoms of schizophrenia.
- Trial name
- NCT01139125
- Testing
- (Cystagon) Cysteamine Bitartrate
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Augusta University
Schizophrenia
The Optimal Treatment for Treatment-resistant Schizophrenia
The Optimal Treatment for Treatment-resistant Schizophrenia
- Trial name
- NCT02926976
- Testing
- Risperidone with Clozapine, Aripiprazole with Clozapine, sodium valproate with Clozapine
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Shanghai Mental Health Center
Schizophrenia and Related Disorders
Improving Cognition Via Exercise in Schizophrenia
People with schizophrenia display a broad range of cognitive impairments that have been identified as major determinants of poor functioning and disability.
- Trial name
- NCT03270098
- Testing
- Aerobic Exercise, Stretching and Toning Exercise
- Where
- 4 sites in United States
- Volunteers
- 104 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Schizophrenia
Bifeprunox in the Treatment of Schizophrenia
Study of the long-term efficacy and safety of bifeprunox in the treatment of schizophrenia. Extension to study S154.3.001.
- Trial name
- NCT00193687
- Testing
- bifeprunox
- Volunteers
- 986 people
- Sponsor
- Solvay Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.